Bortezomab Injection

Bortezomab Injection Specification

Indication
Multiple Myeloma, Mantle Cell Lymphoma

Salt Composition
Bortezomib

Origin
Synthetic

Dosage Form
Injection

Enzyme Types
Proteasome Inhibitor

Feature
Sterile, Preservative Free, Single Use Vial

Ingredients
Each vial contains Bortezomib as active ingredient; mannitol, nitrogen, water for injection as excipients

Application
Antineoplastic, Cancer Therapy

Ph Level
Approx. 4.0 6.0 (after reconstitution)

Fermentation Smell
Odorless

Enzymatic Activity
Inhibits 26S proteasome activity

Storage Instructions
Store below 25C, protect from light

Shelf Life
2 years

Brand Name
Bortezomab

Prescription
Required

Usage Route
Intravenous or Subcutaneous Injection

Strength
2 mg/vial, 3.5 mg/vial (as available)

Reconstitution
Requires reconstitution with normal saline

Contraindications
Hypersensitivity to Bortezomib or any excipients

Marketed By
Pharmaceutical Manufacturer

Patient Age Group
Adults

Bortezomab Injection Trade Information

Supply Ability
1000 Boxes, Per Week

Delivery Time
1 Week

About Bortezomab Injection

Bortezomab:-

VELCADE (bortezomib) for Injection is an antineoplastic agent available for intravenous injection or subcutaneous use. Each single use vial contains 3.5 mg of bortezomib as a sterile lyophilized powder. Inactive ingredient: 35 mg mannitol, USP.

Bortezomib is a modified dipeptidyl boronic acid. The product is provided as a mannitol boronic ester which, in reconstituted form, consists of the mannitol ester in equilibrium with its hydrolysis product, the monomeric boronic acid. The drug substance exists in its cyclic anhydride form as a trimeric boroxine.

The chemical name for bortezomib, the monomeric boronic acid, is [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid.

How Does Bortezomab Injection Work?

Bortezomab Injection acts as a proteasome inhibitor, blocking the activity of the 26S proteasome complex in cells. This interruption leads to the accumulation of proteins within cancer cells, ultimately resulting in cell death and inhibiting tumor growth. Its targeted mechanism is significant for therapies in multiple myeloma and mantle cell lymphoma.

Administration and Usage Instructions

Bortezomab Injection is administered either intravenously or subcutaneously, based on your physicians recommendation. Reconstitution with normal saline must be performed by a healthcare professional before injection. This medication is for adult patients only and should always be administered under medical supervision at clinics or hospitals.

Storage and Handling Guidelines

Keep Bortezomab vials stored below 25C in their original packaging, protected from light. The vials are intended for single use and must be discarded safely after administration. Ensure the medication is reconstituted just before use and not stored once mixed.

FAQs of Bortezomab Injection:

Q: What conditions is Bortezomab Injection prescribed for?

A: Bortezomab Injection is primarily indicated for the treatment of multiple myeloma and mantle cell lymphoma in adult patients. It is used as part of a cancer therapy regimen and must be prescribed by a qualified healthcare provider.

Q: How should Bortezomab Injection be prepared and administered?

A: The injection must be reconstituted with normal saline by a healthcare provider before administration. It is then given either intravenously or subcutaneously in a clinical setting. Patients should never attempt to self-administer this medication.

Q: When is Bortezomab Injection contraindicated?

A: This medication should not be used in patients with known hypersensitivity to bortezomib or any other ingredients in the formulation. Always inform your healthcare provider about your allergies before starting this treatment.

Q: Where should Bortezomab Injection be stored?

A: Store the vials below 25C, away from light, and in their original packaging. Do not freeze the vials and keep them out of the reach of children. Proper storage helps maintain the effectiveness of the medication.

Q: What are the benefits of Bortezomab Injection in cancer therapy?

A: Bortezomab Injection effectively inhibits the growth and survival of cancer cells by blocking proteasome activity. It is an important therapeutic agent that contributes to better treatment outcomes for adults with multiple myeloma and mantle cell lymphoma.